Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting

NCT05048589 is registered in ClinicalTrials.gov with Tor Biering-Sørensen as lead sponsor.

NCT NCT05048589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05048589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting
Lead sponsor
Tor Biering-Sørensen
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2021
Completion date
May 31, 2022
Enrollment
12,551 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza